Drug intelligence / Profile preview

ORK6

Development stage: Preclinical
Lead developer: Orikine Bio
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes

Overview

ORK6 is a preclinical-stage bi-specific cytokine developed by Orikine Bio using its proprietary Foldikine™ platform. It is specifically engineered to treat neuro-inflammatory conditions by reprogramming microglia and Langerhans cells. The Foldikine platform utilizes computational protein design to create cytokines with dual-targeting capabilities, aiming to achieve higher precision and reduced systemic toxicity compared to traditional cytokine therapies. As of 2024, the specific neuro-inflammatory indication remains undisclosed, and Orikine Bio is actively seeking partners for its further development.

Beyond the preview

Go deeper on ORK6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORK6.

Explore the full profile